Sareum Share Discussion Threads

[norma_stitts] 12/8/2022 21:41

I’ve previously held both and done OK from them but I ALWAYS remember ASOS as the ‘better to have luck than talent’ scale.

I sold my entire holding and then they had a warehouse fire. Think it tanked like 20-25% the next day?

I can remember reading the news on my phone at a cruise (car meeting for the uninformed) and chuckling to myself thinking I’d dodged a bullet and lucked out. Fairly certain, without looking, the share price was half what you stated above but time can pickle your mind?

[silvergreyhead1] 12/8/2022 21:03

Hmmmm Critical the top 20 companies on AIM are all worth in the billions so they ain't small fry. They are volatile look at the likes of Boohoo and ASOS two years ago £44 and £4 a share now down 60% but could easily shoot back.That said AIM is full of a lot of shysters CTAG?

[criticalthinker1] 12/8/2022 19:12

From Proactive Investor today...I think we are in a pretty good position personally ...and I think the Board are playing a blinder!!

Larger drugs companies are looking to snap up new technologies or promising treatments before their rivals and are willing to pay well for the privilege

Drug development for smaller, innovative life sciences companies is the corporate equivalent of a high wire act.

Ensuring the cash taps remain open is one challenge. The other is finding the balance between risk and reward.

Very few businesses listed on AIM will or indeed ever have hit a home run – this involves discovering, developing and taking to market a unique new treatment.

Why is this? Well, it’s not because these businesses or their principals lack vision or the courage of their convictions (quite the opposite sometimes).

There is more to the report .... and maybe just maybe we get some noteable and more honoured attention...

Also that £60k buy wasn't too shabby.

[horridhenry] 12/8/2022 17:11

Looks like Emma's stuck £60k in this afternoon

[silvergreyhead1] 12/8/2022 16:47

Nice finish to the week.

[norma_stitts] 12/8/2022 14:36

Swans are a protected species so you can’t eat them.

Personally I like eating shark. Catching the bait used to be quite difficult but it’s simple now. Just buy a PAYGE top up card and find your local hotel filled with illegal immigrants.

Wave the top up card out of the window and they’re like flies around poo. Hey presto a car full of bait and plenty to catch 10 sharks on a good day.

The best bit is the sim card can be reused to catch your next lot, you reduce the tax burden and nobody reports them missing because frankly, nobody gives a toss. 😂

So yeah, get your butler a SIM card, charter a boat and start eating shark.

[horridhenry] 12/8/2022 13:06

there is a lot of this being held at much higher prices, and some at much lower.
Very very small volume so the share price will drift - people sell because for whatever reason they have to, or they invested in the SP, not the company

etc. etc.

Foi Gras, Lobster and Smoked Swan for breakfast tomorrow i think. The butlers just off to the canal for a swan - he dresses up as a female swan, and has to submit to quite a seeing to from several males, before he catches one. He knows his place

[horridhenry] 12/8/2022 12:33

6 buys 5 sells today - all red, actual spread is 161-167

[silvergreyhead1] 12/8/2022 10:08

Just don't see why all the selling at the moment. Maybe people a little scared of the CTA being denied. A little sneaky feeling that maybe folksdidnt think Psoriasis was our best option. Who knows hopefully CTA accepted then into trials and onto the rewards

[norma_stitts] 11/8/2022 23:06

I believe that one should get an initial assessment within 30 days of a clinical trial application being submitted, subject to requesting additional information, so we could hear something by the end of the month?

[criticalthinker1] 11/8/2022 22:08

22nd July. This is not part of our share price too date if it gets approved

Dr Tim Mitchell, CEO of Sareum, commented:

“The CTA application for SDC-1801 is an important milestone as we advance this promising potential new therapeutic into the clinic.

“SDC-1801 is a TYK2/JAK1 inhibitor which we believe has significant potential in autoimmune disease and we plan to explore this initially in psoriasis, where we believe dual inhibition of both TYK2 and JAK1 has the potential to offer superior efficacy compared to small molecules currently available and in development inhibiting each of the targets individually.

“We have completed most of the preparatory work for the clinical trial and have built a robust data package to support our ongoing partnering activities for this asset. Subject to regulatory approval by MHRA, we look forward to advancing SDC-1801 into clinical development.”

...take note

SDC-1801 is a TYK2/JAK1 inhibitor which we believe has significant potential in autoimmune disease and we plan to explore this initially in psoriasis,

Just read what they say...significant...well that requires balls to put that out...and initially...i believe they know this is going to get approved and many other ailments will benefit in due time.
Why else would Tim mention re the Boston online meet what he said..
And fwiw I've asked directly as I can't find the transcript of the Investor Meet.
Personally I believe some of what was discussed live was worthy of a RNS.
All best and I have bacon and eggs with fried bread on my radar tomorrow.
Not even going to mention the ONS recent Excessive deaths since 2020 where the 'weak' apparently passed within 28 days with cough cough and thus excess deaths should be lower. But much higher now. Anyone noticing heart attack increase...if not you are blind.
Anyone care to question my last point should check out ONS excess deaths.
It's happening noteably around me but I'm not looking like a nut job now.

[criticalthinker1] 11/8/2022 13:06

Silver...well GSK will need some good news re the incoming law suits re Zantac. Apparently the case result is due this year.
Pound to a penny Elliot knew this...and rather timely the split of GSK/HALEON......

[silvergreyhead1] 11/8/2022 11:40

Critical perhaps Eliot are going because GSK are going for 737 and they don't like it.Two sides to every coin Critical till the RNS hits.

[criticalthinker1] 10/8/2022 23:47

Well something is happening. And I for one and from what ive read well healed traders/investors are scratching their heads. Blimey. Seems Emma pre divi has got a sh1t storm on her hands. Is Elliot moving on to invest elsewhere? Hands up here i haven't a clue but something is afoot.
Just going to put a random thought out there that is there a possibility he has got wind of sareum and sees potential...(tim said he was involved in the chk boston conference which i asked..that included Abbvie...bet his team were part of it)..of which will see him be aparty to our ipr and also negotiations if any of our recently updated patents get full attention...elsewhere...not too far...
Just my mad speculation but be lovely to see a TR1.
Or a further subscription ....
Just imagine that...the price has become somewhat lower!!!! for a late entrant...and they did mention financial requirements to progress further...
Right I'm off to bed after I've put the unicorns back in their stable.
All best Steadydanny

[silvergreyhead1] 10/8/2022 09:07

Henry it's quite frightening that Octopus thing especially in crystal ball mode. The thing I find strange though is it presumes you won't continue to pay your normal DD when you receive the govt grant.Our usual bill is 67% of the price cap yours is massive compared to ours. Certainly makes sense for you to up sticks for the winter. Might see you on Thoth2s favourite A Place in the Sun.

[horridhenry] 10/8/2022 08:58

Octopus energy has a Balance forecast page based on current usage, telling me that our energy cost will peak at £1,551 in January, and about £10,000 for the year - i think it will be more as the cap is going to change again.

Very tempted to up sticks and move somewhere warm - at least for the Winter. My estimate for November to March 23 is £6,300 - that would get us in a half decent rented warm place for 5 months.